Bender Robert & Associates Evolus, Inc. Transaction History

Bender Robert & Associates

  • $471 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 20, 2023
BUY
$7.81 - $11.05 $195,796 - $277,023
25,070 New
25,070 $212,000
Q2 2022

Jul 19, 2022
BUY
$10.22 - $13.94 $256,215 - $349,475
25,070 New
25,070 $291,000
Q2 2021

Jul 16, 2021
SELL
$8.42 - $13.96 $210,500 - $349,000
-25,000 Closed
0 $0
Q1 2021

Apr 28, 2021
BUY
$3.2 - $16.51 $80,000 - $412,750
25,000 New
25,000 $325,000

Others Institutions Holding EOLS

# of Institutions
168
Shares Held
47.8M
Call Options Held
130K
Put Options Held
51K
View Full List

About Evolus, Inc.

EOLS Quotes by TradingView
  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $608M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Bender Robert & Associates Portfolio

Follow Bender Robert & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bender Robert & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Bender Robert & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email